Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma

Polski Przeglad Chirurgiczny/ Polish Journal of Surgery

Volumn 84, Issue 7, 2012, Pages 341-347

  Bury, Jarosław ^a   Szumiło, Justyna ^b   Da̧browski, Andrzej ^b   Ciechański, Aleksander ^b   Łliwińska, Justyna ^b   Wallner, Grzegorz ^b  

^a Department of General Surgery   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

adenocarcinoma; stomach; survival; survivin; vascular endothelial growth factor; VEGF

Indexed keywords

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; VASCULOTROPIN;

ADENOCARCINOMA; ARTICLE; CANCER STAGING; CHEMISTRY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR;

ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84866067472     PISSN: 0032373X     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10035-012-0057-5     Document Type: Article

References (27)

1. Meyer HJ, Wilke H: Treatment strategies in gastric cancer. Dtsch Arztelb Int 2011; 108: 698-706.
2. Wang TT, Qian XP, Liu BR: Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol 2007; 13: 2784-90.
3. Yasiu W, Oue N, Kuniyasu H: Molecular diagnosis of gastric cancer: present and future. Gastr Cancer 2001; 4: 113-21. (Pubitemid 33123473)
4. Sun YS, Ye ZY, Zhao ZS: Expression of vascular endothelial growth factor C and survivin in gastric carcinoma and their clinical implications. Zhonghua Wei Chang Wai Ke Za Zhi 2006, 9: 264-67.
5. Iordache S, Saftoiu A, Georgescu CV et al.: Vascular endothelial growth factor expression and microvessel density-two useful tools for the assessment of prognosis and survival in gastric cancer patients. J Gastrointestin Liver Dis 2010; 19: 135-39.
6. Li YH, Wang C, Meng K: Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. World J Gastroenterol 2004; 10: 1984-88. (Pubitemid 39029308)
7. Lauwers GY, Carneiro F, Graham DY et al.: Curado MP: Gastric carcinoma. W: Bosman FT, Carneiro F, Hruban RH, Theise ND (red.) WHO Classification of tumors of digestive system. Lyon: IARC 2010; s. 45-80.
8. Wang ZN, Xu HM, Jiang L: Expression of survivin in primary and metastatic gastric cancer cells obtained by laser capture microdissection. World J Gastroenterol 2004; 10: 3094-98. (Pubitemid 39419865)
9. Choi JH, Oh YH: Correlation of Vascular Endothelial Growth Factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma. J Kor Med Sci 2008; 23: 592-97.
10. Dbrowski A, Filip A, Zgodziski W et al.: Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol, 2004. 42,169-72.
11. Li YH, Hu CF, Shao Q: Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 2008; 6: 1.
12. Lu CD, Altieri DC: Expression of a novel antiapoptosis gene, survivin correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-12. (Pubitemid 28217451)
13. Jüttner S, Wissmann C, Jöns T: Vascular Endothelial Growth Factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-40. (Pubitemid 46622052)
14. Wallner G, Ciecha?ski A, D?browski A i wsp.: Znaczenie czynników bFGF i VFGF w surowicy krwi u chorych na raka ?oł?dka. Pol Przegl Chir 2002; 74: 1138-44. (Pubitemid 36070013)
15. Song ZJ, Gong P, Wu YE: Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 2002; 8: 591-95. (Pubitemid 34918647)
16. Abdou AG, Aiad H: Immunohistochemical evaluation of vascular endothelial growth factor (VEGF) in colorectal carcinoma. J Egypt Natl Canc Inst 2006; 18: 311-22.
17. Chen X, Li JS, Liang QP: Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin Med J (Engl) 2008; 121: 881-86.
18. O'Connor DS, Schechner JS, Adida C: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-98. (Pubitemid 30643793)
19. Prewett M, Santiago A, Oconnor W et al.: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-18. (Pubitemid 29503984)
20. Yang JC, Haworth L, Sherry RW et al.: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34. (Pubitemid 36910021)
21. Gruchlik A, Chodurek E, Dzierewicz Z: VEGF-A target of antiangiogenic cancer therapy. Post Biol Kom 2007; 34: 557-80.
22. Polverini PJ, Leibovich SJ: Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51: 635-42. (Pubitemid 15182529)
23. Xing Z, Conway EM, Kang C et al.: Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004; 199: 69-80. (Pubitemid 38076479)
24. Plescia J, Salz W, Xia F et al.: Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005; 5: 457-68. (Pubitemid 40719129)
25. Akhtar M, Gallagher M, Lisa D: Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol 2006; 13: 122-26. (Pubitemid 44341663)
26. Miyachi K, Sasaki K, Onodera S: Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastr Cancer 2003; 6: 217-24. (Pubitemid 38140003)
27. Schultz IJ, Kiemeney LA, Witjes JA: Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003; 23: 3327-31. (Pubitemid 36975431)